Key result
Targeted lifestyle changes and pharmacotherapy slow atherosclerosis progression in pediatric lipid disorders.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Early lipid screening beginning at 9-11 years of age enables earlier identification of dyslipidemia, including familial hypercholesterolemia (FH), offering opportunity for intervention prior to accumulation of atherogenic exposure.”
Childhood offers a unique opportunity for preventing or slowing atherosclerosis through targeted lifestyle interventions and, when warranted, pharmacotherapy for lipid disorders.
Current scientific evidence has proven that atherosclerosis is a process that begins in childhood and tracks into adulthood, likely culminating in adverse cardiovascular events such as coronary artery disease, peripheral artery disease, and stroke. In addition, the obesity epidemic and increasing awareness of genetic lipid disorders has made the understanding and management of lipid disorders necessary for pediatricians. Childhood offers a unique opportunity for preventing, modifying, or eliminating risk factors and, in doing so, reversing or slowing the process of atherosclerosis. In general, management involves targeted lifestyle interventions such as strict dietary changes and increases in physical activity. In some circumstances, pharmacotherapy, even in childhood, is warranted. [ Pediatr Ann . 2021;50(3):e105–e112.]
No takes yet. Share an insight, caveat, or question.
Leopold et al. (2021) conducted a review in Pediatric Lipid Disorders. Lifestyle interventions and pharmacotherapy was evaluated. Management of pediatric lipid disorders involves targeted lifestyle interventions and sometimes pharmacotherapy to prevent or slow the progression of atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: